Sector Alpha

Track where the smart money flows in Indian equities

DashboardWeekly UpdateSector Deep DivesUploadPipelinePE CyclesBrainAboutHow We Research

Data updated weekly. Not financial advice.

sectoralpha · stock story
Chemicals - Organic →
Home›Stocks›Sacheerome Ltd
SACHEEROMESacheerome LtdChemicals - Organic
₹315+99.5% 1y

Sacheerome Ltd (SACHEEROME) — share price & stock analysis

Profits have nearly tripled in two years.

STEADY GROWTHBeating NIFTY 500 for 7 weeks
STAGE 2 UPTREND
COMPOUNDERNO REAL DEBT
₹705 Cr
Market cap
24.8×
P/E
27.0%
ROE
By Sector Alpha Research · machine-compiled from Screener.in data · Updated 1 July 2026 · Sources: Screener.in company page, NSE quote · Not investment advice
The 30-second answer

Sacheerome Ltd (SACHEEROME) trades at ₹315 as of 1 July 2026, up 100% over the past year — beating NIFTY 500 for 7 weeks. The machine reads this as steady growth: profits have nearly tripled in two years. the price is in Stage 2 — advancing, 51 weeks in. Fundamentals-momentum score: 100/100 (all improving).

Data as of 1 July 2026 · every number traces to its Screener source column · not investment advice.

Key numbers
Market cap
₹705 Cr
P/E
24.8×
ROE
27.0%
Book value / share
₹66.3
Revenue (FY26)
₹152 Cr
Profit after tax (FY26)
₹28 Cr
Weinstein stage
Stage 2 (51 weeks)
Data as of
1 July 2026
MOMENTUM OF THE FUNDAMENTALS
100/100
ALL IMPROVING
Levels: ROCE 36% — a high-quality engine · effectively no debt · margins at an all-time high
MarginsOPM 22.1% → 22.8% in a year
Cash generationOperating cash ₹10.0 Cr → ₹22.0 Cr
Balance sheetDebt is ₹0 per ₹100 of shareholders’ money

3 of the 3 things we track are currently moving the right way — nearly everything is pulling in the same direction.

Where the levels actually stand: ROCE 36% — a high-quality engine; effectively no debt; margins at an all-time high. Momentum says which way things are moving; these say where they are.

Read this number for what it is: it measures the DIRECTION of change, not the quality of the business. A mediocre business getting better scores high here; a great one having a soft quarter scores low. Profit, sales and margins count double.

WHERE THE PRICE IS IN ITS CYCLE

The price is in a confirmed uptrend — 51 weeks and counting

STAGE 2 · ADVANCING · 51 WEEKS

Stock prices move through four repeating stages: basing (1), advancing (2), topping (3) and declining (4). This one is in Stage 2: advancing, 51 weeks in, confirmed.stage

The price sits above its rising 200-day average (₹312 today) — trends like this persist more often than they reverse, which is why the system rides them instead of guessing the top.dma_200

Beating NIFTY 500 for 7 weeks — relative strength is the market’s live opinion, and right now it is on this stock’s side.rs_mansfield

What would end it: two Friday closes in a row below the 200-day line. That is the house exit rule — mechanical, no debates.dma_200

Weekly price with its 200-day and 50-day averages — stages shaded₹weinstein_stages
S2200300400Price200-DMAStage 2 began · Aug 25Jun 25Oct 25Mar 26Jul 26
Data: Weekly price, moving averages and stage
PeriodPrice (₹)200-DMA (₹)50-DMA (₹)Stage
Jun 251551611604
Jun 251581601594
Jul 251601601594
Jul 252091611624
Jul 251851621674
Jul 251751631694
Aug 252041641722
Aug 251821651752
Aug 251871661772
Aug 251771671782
Aug 252011681812
Sep 252001701842
Sep 252121711872
Sep 252281741962
Sep 252101762002
Oct 252201782022
Oct 252091802042
Oct 252031812042
Oct 252151822062
Oct 252221842092
Nov 252181862102
Nov 253081892202
Nov 253571962392
Nov 253592042602
Dec 253382102752
Dec 254082192942
Dec 253542273112
Dec 253422323172
Jan 263762393272
Jan 264102473422
Jan 263912533492
Jan 263662593542
Feb 263702643572
Feb 263702683592
Feb 263562723582
Feb 263652763572
Feb 263882823622
Mar 263812863662
Mar 263712903682
Mar 263272933622
Mar 262802923502
Apr 263592993512
Apr 263533013532
Apr 263333033512
May 263503053512
May 263223073492
May 263353083462
May 263323093442
Jun 263093093392
Jun 263233103392
Jun 263363103392
Jun 263293113392
Jun 263233113362
Jun 263243113352
Jun 263133123332
Jun 263173123322
Jul 263153123302
THE LONG ARC

Profits have grown in 4 of the last 4 years — compounding so far, on a short record

Over 4 years, sales went from ₹64.0 Cr to ₹152 Cr (about 24% a year), and profit from ₹5.0 Cr to ₹28.0 Cr.revenuenet_profit

Margins widened 10.2 points along the way — growth with improving economics.operating_profit

Revenue by year₹ Crannual_results
050.0100150FY22FY24FY26
Data: Revenue by year
PeriodRevenue (₹ Cr)
FY2264
FY2370
FY2485
FY25108
FY26152
Profit by year₹ Crannual_results
010.020.030.0FY22FY24FY26
Data: Profit by year
PeriodProfit after tax (₹ Cr)
FY225
FY236
FY2411
FY2516
FY2628
OPM % by year%annual_results
15.020.025.0FY22FY24FY26
Data: OPM % by year
PeriodOPM % (%)
FY2214.1
FY2314.3
FY2417.6
FY2521.3
FY2624.3
CHAPTER 1 · THE ACID TEST

The profits are real — they turn into cash

Operating cash flow (CFO) — the cash that actually arrived, vs PAT, the profit accounting reports. Annual figures.

Over the last 4 profitable years, the business reported ₹38.0 Cr of profit and collected ₹52.0 Cr of operating cash — about 137% conversion.operating_cash_flownet_profit

When cash tracks profit this closely, the earnings need no asterisk.

Cash collected vs profit reported (annual)₹ Crcash_flow
510.015.020.0Operating cash flowProfit after taxFY22FY24FY25
Data: Cash collected vs profit reported (annual)
PeriodOperating cash flow (₹ Cr)Profit after tax (₹ Cr)
FY229.05.0
FY2311.06.0
FY2410.011.0
FY2522.016.0
CHAPTER 2 · THE PIPELINE

The cash cycle is stable

Working capital — days of sales locked up in inventory and unpaid bills. Screener reports this yearly, so this chart is annual.

One rupee now takes about 34 days to go out the door as materials and come back as collected cash.cash_conversion_cycle

The biggest mover: suppliers being paid sooner (80 → 61 days).payable_days

Days of cash locked up (annual)daysratios
6080100Customers owe (debtor days)Stock on shelf (inventory days)We owe suppliers (payable days)FY22FY24FY26
Data: Days of cash locked up (annual)
PeriodCustomers owe (debtor days) (days)Stock on shelf (inventory days) (days)We owe suppliers (payable days) (days)
FY2267.011371.0
FY2363.010073.0
FY2468.085.073.0
FY2552.063.080.0
FY2647.047.061.0
CHAPTER 3 · THE BUILD

Building hard — new capacity is under construction

Capex — money spent on plants, machines and buildings. Gross block is what exists; CWIP (capital work-in-progress) is what is being built. Annual.

The productive asset base has gone from ₹9.0 Cr (FY22) to ₹23.0 Cr, with another ₹57.0 Cr of capacity under construction right now.fixed_assetscwip

Work-in-progress is 248% of the existing asset base — that is a serious bet on future demand. Capacity like this shows up in sales with a lag; it is tomorrow’s growth being paid for today.cwip

The build is self-funded: the last 3 years' investing outflow (₹35.0 Cr) fits inside the operating cash the business generated (₹43.0 Cr).investing_cash_flowoperating_cash_flow

Assets in place vs under construction (annual)₹ Crbalance_sheet
020.040.060.0Fixed assetsUnder construction (CWIP)FY22FY24FY26
Data: Assets in place vs under construction (annual)
PeriodFixed assets (₹ Cr)Under construction (CWIP) (₹ Cr)
FY229.00.0
FY2321.02.0
FY2422.08.0
FY2523.028.0
FY2623.057.0
WATCH →When CWIP converts to assets, sales must follow — two years of rising assets with flat sales would mean the bet is not paying.
CHAPTER 4 · SURVIVAL

Almost no debt — this company cannot be killed by a bad year

Debt-to-equity — borrowings against shareholders’ money. Computed from the balance sheet. Annual.

For every ₹100 shareholders have put in (and left in), the company has borrowed ₹0 — total borrowings have shrunk from ₹8.0 Cr to ₹0.0 Cr over the window.borrowings

Total borrowings (annual)₹ Crbalance_sheet
02.557.5FY22FY24FY26
Data: Total borrowings (annual)
PeriodBorrowings (₹ Cr)
FY228.0
FY230.0
FY241.0
FY253.0
FY260.0
Debt vs shareholders’ money (annual)xbalance_sheet
00.10.20.3FY22FY24FY26
Data: Debt vs shareholders’ money (annual)
PeriodDebt ÷ equity (x)
FY220.3
FY230.0
FY240.0
FY250.1
FY260.0
THE VERDICT

Worth studying deeper — with eyes open

The numbers lean positive, and the price is roughly fair to the delivery so far.

Best thing in the data: cash generation rising (₹10.0 Cr → ₹22.0 Cr).operating_cash_flow

Biggest worry: foreign-fund holding falling (1.5% → 0.2%).fiis_pct

The machine committee — 7 independent readsSTUDY DEEPER · 66%
Earnings patternNEUTRAL10% · w21
Valuation cyclePOSITIVE81% · w19
CatalystsPOSITIVE30% · w14
Quality & safetyPOSITIVE58% · w14
TechnicalsNEUTRAL20% · w12
ValuationPOSITIVE40% · w10
Growth at a pricePOSITIVE52% · w10
7-model research readSTUDY DEEPER · 66% confidence
WHAT WOULD CHANGE THIS VIEWTwo quarters of profit reversing would kill this story.

Machine-written research from Screener data — every number traces to its source column. Sector Alpha is not a SEBI-registered investment adviser; nothing here is a recommendation to buy or sell. Not investment advice.

More Chemicals - Organic stocks
Fine Organic Industries LtdBASF India LtdElantas Beck India LtdBalaji Amines LtdLaxmi Organic Industries LtdFoseco India LtdAll Chemicals - Organic stocks →
Frequently asked questions

Straight answers from the data

What does Sacheerome Ltd do?

Incorporated in 2009, Sacheerome Ltd is in the business of designing & manufacturing fragrance and flavours[1]. It is listed in the Chemicals - Organic sector with a market capitalisation of ₹705 Cr.

What is Sacheerome Ltd's share price?

As of 1 July 2026, Sacheerome Ltd trades at ₹315, up 100% over the past year, with a market capitalisation of ₹705 Cr. Beating NIFTY 500 for 7 weeks. Prices are weekly closes from Screener data; this page refreshes with each weekly update.

What is Sacheerome Ltd's share price target?

Sector Alpha does not publish broker-style price targets. Our discounted-cash-flow model estimates Sacheerome Ltd's intrinsic value at ₹665 per share under base assumptions (bear ₹223, bull ₹665), against the current price of ₹315 — a 98% margin of safety. These are model estimates, not forecasts — treat them as one input alongside the valuation history below, not as a target.

What is Sacheerome Ltd's long-term growth record?

Revenue grew from ₹64 Cr in FY22 to ₹152 Cr in FY26 — a 24.1% compound annual growth rate over 4 years. Profit after tax compounded at 53.8% over the same period (₹5 Cr → ₹28 Cr).

Is Sacheerome Ltd stock in an uptrend?

The price is in a confirmed uptrend — 51 weeks and counting. Sacheerome Ltd is in Stage 2 — advancing, 51 weeks in (confirmed). Stages follow Stan Weinstein's four-phase read of weekly price against the 200-day average: basing (1), advancing (2), topping (3), declining (4).

Why is Sacheerome Ltd stock rising?

The price is up 100% over the past year, in a confirmed Stage 2 uptrend (51 weeks), and has beaten NIFTY 500 for 7 weeks.

Is Sacheerome Ltd beating the NIFTY 500?

Yes — beating NIFTY 500 for 7 weeks, as of 1 July 2026. Relative strength is measured weekly against the NIFTY 500 (Mansfield RS): a positive reading means the stock has outperformed the index over the trailing window, week after week.

Does Sacheerome Ltd have too much debt?

Almost no debt — this company cannot be killed by a bad year. For every ₹100 shareholders have put in (and left in), the company has borrowed ₹0 — total borrowings have shrunk from ₹8.0 Cr to ₹0.0 Cr over the window.

What is the bull case for Sacheerome Ltd?

Profits have nearly tripled in two years. Best thing in the data: cash generation rising (₹10.0 Cr → ₹22.0 Cr).

What is the bear case for Sacheerome Ltd — what could break the story?

Biggest worry: foreign-fund holding falling (1.5% → 0.2%). Two quarters of profit reversing would kill this story. The nearest-term thing to watch: when CWIP converts to assets, sales must follow — two years of rising assets with flat sales would mean the bet is not paying. This falsification condition is stated up front so the thesis can be checked against incoming quarters, not defended after the fact.

Is Sacheerome Ltd a stock worth studying right now?

Sector Alpha does not publish buy or sell recommendations — this is a research read, not advice. What the data says: worth studying deeper — with eyes open. The numbers lean positive, and the price is roughly fair to the delivery so far. Across the 7-model scorecard the composite research signal is study deeper at 66% confidence. This is machine-written research compiled from Screener data — every number traces to its source — and it is not investment advice. Do your own diligence.

Generated from Screener data · 11 sources · why_traces/1.0 + story/1.2
details
generated 2026-07-03 11:21 · 8 material moves detected
sources: screener_company_info, screener_quarterly_results, screener_annual_results, screener_valuation_history, screener_shareholding, screener_cash_flow, screener_ratios, screener_balance_sheet, screener_margin_trends, weinstein_stages, agent_scores